Ocular Therapeutix, Inc. announced that it has entered into a securities purchase agreement with certain institutional accredited investors , pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 32,413,560 shares of the Company?s common stock, par value $0.0001 per share at a price of $7.52 per share for the gross proceeds of $243,749,971.2? and pre-funded warrants to purchase 10,805,957 shares of the Company?s common stock at a price of $7.519 per Pre-Funded Warrant for the gross proceeds of $81,249,990.683 for the aggregate gross proceeds of $324,999,961.883 on February 21, 2024. The transaction is expected to close on February 26, 2024, subject to the satisfaction of certain customary closing conditions. The Company has granted the Investors indemnification rights with respect to its representations, warranties, covenants and agreements under the Securities Purchase Agreement.

Each Pre-Funded Warrant to be issued in the Private Placement will have an exercise price of $0.001 per share, will be exercisable immediately and will be exercisable until the Pre-Funded Warrant is exercised in full.